

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **VOLUNTARY ANNOUNCEMENT STRATEGIC COOPERATION FRAMEWORK AGREEMENT**

This announcement is made by Tianda Pharmaceuticals Limited (the “Company”) on a voluntary basis. The purpose of this announcement is to keep the shareholders of the Company and potential investors informed of the latest business development of the Company.

### **Strategic Cooperation Framework Agreement**

The Company is pleased to announce that on 9 November 2021 (after trading hours), the Company entered into a strategic cooperation framework agreement (the “Framework Agreement”) with Zhong Ji Longevity Science Group Limited (“Zhong Ji Longevity Science”) in relation to a strategic cooperation in the following areas for a term of three years:

- (1) The parties will jointly evaluate and invest in potential medical technology and medical service projects, including equity investment in other listed companies and unlisted projects;
- (2) The Company, which operates the modern Chinese medicine clinic chain “TDMall” and health management centre, will recommend to its members of the longevity medical services offered by Zhong Ji Longevity Science, and will provide quality Chinese medicine services to the members of Zhong Ji Longevity Science; and
- (3) Zhong Ji Longevity Science, which operates longevity medical examination services and provides scientific solutions for health and longevity, will recommend to its members of the Chinese medicine services offered by the Company, and will provide quality longevity medical services to the members of the Company.

## **Information of Zhong Ji Longevity Science**

Zhong Ji Longevity Science (SEHK stock code: 0767.HK) is principally engaged in the business of longevity science, money lending, securities and other investment, financial and investment advisory as well as property investment. Zhong Ji Longevity Science is a leading ecosystem platform in longevity science and is operating through five key divisions, namely longevity science research division for R&D, longevity medical testing division for provision of health data and longevity medical examination services, longevity biological products division for production and sales of longevity biological products including NMN and VC sustained-release tablets, longevity management services division for providing scientific solutions for health and longevity, and membership division for operation of the World Longevity Science and Health Club.

## **Reasons and benefits of entering into the Framework Agreement**

The Company continues to implement the strategies of “development of Chinese medicine as foundation, development of innovative drugs and medical technologies, as well as development of quality medical and healthcare services”, striving to become a leading pharmaceutical enterprise setting its footholds in China with business presence worldwide. The Company is of the view that entering into the Framework Agreement will enhance the in-depth cooperation and resource sharing between the Company and its strategic partner in investment development and business development, the sourcing and evaluation of potential investment opportunities in the field of medical technology and service, as well as the integration with Chinese medicine, modern medicine and other innovative technologies, allowing the Company to provide quality medical and healthcare services to its customers.

By order of the Board  
**Tianda Pharmaceuticals Limited**  
**FANG Wen Quan**  
*Chairman and Managing Director*

Hong Kong, 10 November 2021

*As at the date of this announcement, the executive Directors are Mr. FANG Wen Quan (Chairman and Managing Director) and Mr. LUI Man Sang; the non-executive Directors are Mr. SHEN Bo and Mr. FENG Quanming; and the independent non-executive Directors are Mr. LAM Yat Fai, Mr. CHIU Sung Hong and Mr. CHIU Fan Wa.*